1. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

human rhabdomyosarcoma cell

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

1

Peptides

1

Inhibitory Antibodies

1

Natural
Products

Art. -Nr. Produktname Target Forschungsgebiete Chemical Structure
  • HY-P99974
    Nab-Paclitaxel
    4 Publications Verification

    Nanoparticle albumin-bound Paclitaxel; Nanoparticle albumin-bound ABI-007

    Microtubule/Tubulin Apoptosis Autophagy Cancer
    Nab-Paclitaxel (Nanoparticle albumin-bound Paclitaxel) is an albumin-bound nanoparticle formulation of Paclitaxel (HY-B0015). Nab-Paclitaxel is composed of albumin and the active pharmaceutical ingredient Paclitaxel, in which human albumin is used as an excipient to disperse and stabilize particles and carry the main drug. Nab-Paclitaxel is a solvent-free taxane with higher response rates and improved tolerability. Nab-Paclitaxel displays less toxicity and greater antitumor activity. Nab-Paclitaxel is more readily available for tumor cell uptake in three rhabdomyosarcoma, seven neuroblastoma cell lines, and one ostersarcoma cell line Nab-Paclitaxel can be studied in cancer research for example breast cancer and solid tumors. (The product specifications below only indicate the effective content of Paditaxel, the actual albumin quality depends on the batch; the ratio of each ingredient in this product is Paditaxel: albumin -1:7~1:11) .
    Nab-Paclitaxel
  • HY-14925
    Lapaquistat
    2 Publications Verification

    T-91485

    Endogenous Metabolite Drug Metabolite Metabolic Disease
    Lapaquistat (T-91485), a cholesterol biosynthesis inhibitor, is the active metabolite of Lapaquistat acetate (HY-16274). Lapaquistat can decrease statin-induced myotoxicity in lipid-lowering therapy .
    Lapaquistat
  • HY-124843
    LLL3
    1 Publications Verification

    CLT-005

    STAT Apoptosis Cancer
    LLL3 (CLT-005) is a STAT3 inhibitor. LLL3 inhibits dimerization and phosphorylation of STAT3, thereby preventing intraconuclear transfer of STAT3 and inhibits the expression of STAT3 dependent genes, which encode proteins such as Bcl-xL and cyclin D1. In addition, LLL3 can induce cell growth inhibition and apoptosis in human breast cancer and rhabdomyosarcoma cells via the caspase pathway. LLL3 can be used in the study of STAT3 persistent activation types of cancer .
    LLL3
  • HY-P3571

    Endothelin Receptor Cancer
    [Ala2] Endothelin-3, human is a linear analog of endothelin-3 (ET-3) where substitution of Ala for Cys residues. TE-3 is a vasoactive peptide, produced by human rhabdomyosarcoma cell lines, whereas it is not expressed by human sarcoma cell lines of non-muscle origin. ET-3 acts as a paracrine factor, since it promotes migration of endothelial cells .
    [Ala2] Endothelin-3, human
  • HY-182403

    Apoptosis Others Cancer
    GR-891 is an acyclic nucleoside 5-Fluorouracil (HY-90006) derivative. GR-891 exerts antiproliferative activity in human cancer cells and inhibits proliferation of human rhabdomyosarcoma cells. GR-891 induces terminal myogenic differentiation in human rhabdomyosarcoma cells, including modulation of desmin and vimentin expression. GR-891 is phosphorylated by kinases, incorporated into RNA, and releases acrolein. GR-891 can be used for the research of cancer and rhabdomyosarcoma .
    GR-891
  • HY-184150

    Ligands for E3 Ligase E1/E2/E3 Enzyme Others
    EN10 is a ligand for the muscle-specific E3 ligase KLHL41, which can be used to synthesize PROTAC KBD-1 (HY-184151) targeting BRD4 .
    EN10
  • HY-184151

    PROTACs Epigenetic Reader Domain Cancer
    KBD-1 is a muscle-specific BRD4 PROTAC degrader with human KDs of 27.04 nM and 37.36 µM against BRD4 and KLHL4L, respectively. KBD-1 recruits the muscle-specific E3 ligase KLHL41, mediating Cullin-RING ligase (CRL)-dependent ubiquitination and proteasome degradation of BRD4. KBD-1 can be used for the research of myosarcoma .
    KBD-1

Online-Anfrage

Your information is safe with us. * Required Fields.

Anrede

 

Country or Region *

Name des Antragstellers *

 

Name der Organisation *

Department *

     

E-Mail-Addresse *

 

Produktname *

Art. -Nr.

 

Requested quantity *

Telefonnummer *

     

Bemerkungen

Online-Anfrage

Inquiry Information

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent: